Is Biomarin Pharmaceutical Stock a Good Investment?
Biomarin Pharmaceutical Investment Advice | BMRN |
- Examine Biomarin Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomarin Pharmaceutical's leadership team and their track record. Good management can help Biomarin Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biomarin Pharmaceutical's business and its evolving consumer preferences.
- Compare Biomarin Pharmaceutical's performance and market position to its competitors. Analyze how Biomarin Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Biomarin Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomarin Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomarin Pharmaceutical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomarin Pharmaceutical is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Biomarin Pharmaceutical Stock
Researching Biomarin Pharmaceutical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 26.74. The company has Price/Earnings To Growth (PEG) ratio of 0.76. Biomarin Pharmaceutical had not issued any dividends in recent years.
To determine if Biomarin Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomarin Pharmaceutical's research are outlined below:
| Biomarin Pharmaceutical generated a negative expected return over the last 90 days | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: BioMarin Pharmaceutical Inc. Beat Analyst Estimates See What The Consensus Is Forecasting For This Year - Yahoo Finance |
Biomarin Pharmaceutical Quarterly Cash And Short Term Investments |
|
Biomarin Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biomarin Pharmaceutical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biomarin Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Biomarin Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Biomarin Pharmaceutical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2008-08-05 | 2008-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
2008-02-26 | 2007-12-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2009-07-30 | 2009-06-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2008-10-28 | 2008-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2007-08-07 | 2007-06-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2007-02-20 | 2006-12-31 | -0.13 | -0.11 | 0.02 | 15 | ||
2003-08-05 | 2003-06-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2022-10-26 | 2022-09-30 | -0.01 | -0.04 | -0.03 | 300 |
Know Biomarin Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Biomarin Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biomarin Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Norges Bank | 2023-12-31 | 3.4 M | Elliott Investment Management L.p. | 2023-12-31 | 3 M | Geode Capital Management, Llc | 2023-12-31 | 2.9 M | Hhg Plc | 2023-12-31 | 2.8 M | Bank Of New York Mellon Corp | 2023-12-31 | 2.6 M | Jpmorgan Chase & Co | 2023-12-31 | 2.4 M | Bank Of America Corp | 2023-12-31 | 2.4 M | Nomura Holdings Inc | 2023-12-31 | 2.1 M | Parnassus Investments Llc | 2023-12-31 | 1.8 M | Primecap Management Company | 2023-12-31 | 18.4 M | Vanguard Group Inc | 2023-12-31 | 18.1 M |
Biomarin Pharmaceutical's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 15.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biomarin Pharmaceutical's market, we take the total number of its shares issued and multiply it by Biomarin Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Biomarin Pharmaceutical's profitablity analysis
Biomarin Pharmaceutical's profitability indicators refer to fundamental financial ratios that showcase Biomarin Pharmaceutical's ability to generate income relative to its revenue or operating costs. If, let's say, Biomarin Pharmaceutical is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biomarin Pharmaceutical's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biomarin Pharmaceutical's profitability requires more research than a typical breakdown of Biomarin Pharmaceutical's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.02 | 0.03 | |
| Return On Equity | 0.03 | 0.04 |
Determining Biomarin Pharmaceutical's profitability involves analyzing its financial statements and using various financial metrics to determine if Biomarin Pharmaceutical is a good buy. For example, gross profit margin measures Biomarin Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomarin Pharmaceutical's profitability and make more informed investment decisions.
The data published in Biomarin Pharmaceutical's official financial statements usually reflect Biomarin Pharmaceutical's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Biomarin Pharmaceutical. For example, before you start analyzing numbers published by Biomarin accountants, it's critical to develop an understanding of what Biomarin Pharmaceutical's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Biomarin Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomarin Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Biomarin Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biomarin Pharmaceutical. Please utilize our Beneish M Score to check the likelihood of Biomarin Pharmaceutical's management manipulating its earnings.
Evaluate Biomarin Pharmaceutical's management efficiency
Biomarin Pharmaceutical has return on total asset (ROA) of 0.0177 % which means that it generated a profit of $0.0177 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0422 %, meaning that it created $0.0422 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of May 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 3rd of May 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 26.36 | 27.68 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 23.75 | 24.94 | |
| Enterprise Value Over EBITDA | 70.58 | 74.10 | |
| Price Book Value Ratio | 3.66 | 3.99 | |
| Enterprise Value Multiple | 70.58 | 74.10 | |
| Price Fair Value | 3.66 | 3.99 | |
| Enterprise Value | 15 B | 9.8 B |
The analysis of Biomarin Pharmaceutical's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Biomarin Pharmaceutical's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Biomarin Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.32 |
Basic technical analysis of Biomarin Stock
As of the 3rd of May, Biomarin Pharmaceutical shows the Mean Deviation of 1.15, risk adjusted performance of (0.02), and Standard Deviation of 1.77. Biomarin Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Biomarin Pharmaceutical, which can be compared to its peers. Please confirm Biomarin Pharmaceutical variance and potential upside to decide if Biomarin Pharmaceutical is priced correctly, providing market reflects its regular price of 83.8 per share. Given that Biomarin Pharmaceutical has information ratio of (0.08), we suggest you to validate Biomarin Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.Biomarin Pharmaceutical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomarin Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomarin Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biomarin Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bienaime Jean Jacques over three weeks ago Disposition of 1000 shares by Bienaime Jean Jacques of Biomarin Pharmaceutical at 90.35 subject to Rule 16b-3 | ||
Erin Burkhart over a month ago Disposition of 372 shares by Erin Burkhart of Biomarin Pharmaceutical at 83.87 subject to Rule 16b-3 | ||
George Davis over two months ago Acquisition by George Davis of 20840 shares of Biomarin Pharmaceutical subject to Rule 16b-3 |
Biomarin Pharmaceutical's Outstanding Corporate Bonds
Biomarin Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomarin Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomarin bonds can be classified according to their maturity, which is the date when Biomarin Pharmaceutical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Biomarin Pharmaceutical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Biomarin Pharmaceutical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 1.15 | |||
| Coefficient Of Variation | (2,069) | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.15 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 12.77 | |||
| Value At Risk | (2.32) | |||
| Potential Upside | 2.37 | |||
| Skewness | (2.47) | |||
| Kurtosis | 13.55 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 1.15 | |||
| Coefficient Of Variation | (2,069) | |||
| Standard Deviation | 1.77 | |||
| Variance | 3.15 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 12.77 | |||
| Value At Risk | (2.32) | |||
| Potential Upside | 2.37 | |||
| Skewness | (2.47) | |||
| Kurtosis | 13.55 |
Consider Biomarin Pharmaceutical's intraday indicators
Biomarin Pharmaceutical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biomarin Pharmaceutical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Biomarin Pharmaceutical Corporate Filings
10Q | 26th of April 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 24th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 9th of April 2024 Other Reports | ViewVerify |
Biomarin Stock media impact
Far too much social signal, news, headlines, and media speculation about Biomarin Pharmaceutical that are available to investors today. That information is available publicly through Biomarin media outlets and privately through word of mouth or via Biomarin internal channels. However, regardless of the origin, that massive amount of Biomarin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biomarin Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomarin Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomarin Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomarin Pharmaceutical alpha.
Biomarin Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biomarin Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biomarin Pharmaceutical Historical Investor Sentiment
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biomarin Pharmaceutical.
Biomarin Pharmaceutical Maximum Pain Price across 2024-05-17 Option Contracts
Biomarin Pharmaceutical's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biomarin Pharmaceutical close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biomarin Pharmaceutical's options.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Biomarin Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Biomarin Pharmaceutical Corporate Directors
Biomarin Pharmaceutical corporate directors refer to members of a Biomarin Pharmaceutical board of directors. The board of directors generally takes responsibility for the Biomarin Pharmaceutical's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Biomarin Pharmaceutical's board members must vote for the resolution. The Biomarin Pharmaceutical board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Elaine Heron | Independent Director | Profile | |
| Dennis Slamon | Director | Profile | |
| Robert Hombach | Independent Director | Profile | |
| Richard Meier | Independent Director | Profile |
How to buy Biomarin Stock?
To provide specific investment advice or recommendations on Biomarin Pharmaceutical stock, we recommend investors consider the following general factors when evaluating Biomarin Pharmaceutical. This will help you to make an informed decision on whether to include Biomarin Pharmaceutical in one of your diversified portfolios:- Examine Biomarin Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomarin Pharmaceutical's leadership team and their track record. Good management can help Biomarin Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Biomarin Pharmaceutical's business and its evolving consumer preferences.
- Compare Biomarin Pharmaceutical's performance and market position to its competitors. Analyze how Biomarin Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Biomarin Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomarin Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomarin Pharmaceutical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomarin Pharmaceutical is a good investment.
Already Invested in Biomarin Pharmaceutical?
The danger of trading Biomarin Pharmaceutical is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Biomarin Pharmaceutical is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Biomarin Pharmaceutical. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Biomarin Pharmaceutical is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Biomarin Pharmaceutical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.